3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
63
Breast Neoplasms
63
Carcinoma, Non-Small-Cell Lung
39
Triple Negative Breast Neoplasms
29
Ovarian Neoplasms
25
Fallopian Tube Neoplasms
22
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
16
Stomach Neoplasms
11
Neoplasm Metastasis
11
Neoplasms
9
Inflammatory Breast Neoplasms
9
Breast Neoplasms, Male
9
Melanoma
7
Esophageal Neoplasms
7
Cholangiocarcinoma
7
Uterine Cervical Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Endometrial Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Pancreatic Adenocarcinoma
5
Gallbladder Neoplasms
5
Adenocarcinoma Of Esophagus
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Recurrence
4
Carcinoma, Transitional Cell
4
Biliary Tract Neoplasms
4
Prostatic Neoplasms
3
Peritoneal Neoplasms
3
Interventions
Fulvestrant
6
olaparib
4
Letrozole
4
trastuzumab deruxtecan
3
Aromatase Inhibitors
3
Anastrozole
3
sacituzumab govitecan
2
pyrotinib
2
eribulin
2
dalpiciclib
2
Paclitaxel
2
Goserelin
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Capecitabine
2
toripalimab
1
talazoparib
1
sonidegib
1
ribociclib
1
pembrolizumab
1
neratinib
1
liposomal doxorubicin
1
elacestrant
1
disitamab vedotin
1
ceralasertib
1
capivasertib
1
balixafortide
1
apatinib
1
abemaciclib
1
Vorinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Breast Cancer
×
Taxes
×
Clear all
NCT04826016
2023-03-20
POLTER
MedSIR
Phase 1/2
Withdrawn